View DividendLevel Bio マネジメントマネジメント 基準チェック /14現在、CEO に関する十分な情報がありません。主要情報Joakim Granemo最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間2.8yrsCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間5yrs経営陣の近況Board Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.お知らせ • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.すべての更新を表示Recent updatesBoard Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 02Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO).Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.お知らせ • Feb 12Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million.Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023).お知らせ • Mar 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024お知らせ • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.Reported Earnings • Feb 25Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022).お知らせ • Jan 24AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024Reported Earnings • Oct 29Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr6.54m (up 19% from 3Q 2022). Net loss: kr2.30m (loss widened 93% from 3Q 2022).お知らせ • Sep 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023Reported Earnings • Aug 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022).お知らせ • Jul 26AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023お知らせ • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.Reported Earnings • Apr 20First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022).Buying Opportunity • Apr 03Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 31%. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.Buying Opportunity • Mar 07Now 37% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Feb 24Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021).お知らせ • Jan 18AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021).Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 22First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates.Reported Earnings • Nov 01Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020).Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue.CEO報酬分析Level Bio の収益と比較して、Joakim Granemo の報酬はどのように変化したか？日付総報酬給与会社業績Mar 31 2026n/an/a-SEK 3mDec 31 2025n/an/a-SEK 4mSep 30 2025n/an/a-SEK 4mJun 30 2025n/an/a-SEK 5mMar 31 2025n/an/a-SEK 6mDec 31 2024n/an/a-SEK 8mSep 30 2024n/an/a-SEK 11mJun 30 2024n/an/a-SEK 12mMar 31 2024n/an/a-SEK 11mDec 31 2023SEK 1mSEK 981k-SEK 9mSep 30 2023n/an/a-SEK 5mJun 30 2023n/an/a-SEK 4mMar 31 2023n/an/a-SEK 4mDec 31 2022SEK 866kSEK 768k-SEK 2m報酬と市場: Joakimの 総報酬 がGerman市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。報酬と収益: Joakimの報酬は増加しましたが、会社は利益を上げていません。CEOJoakim Granemo (39 yo)2.8yrs在職期間Mr. Joakim Granemo is Chief Executive Officer of Level Bio AB (publ) from August 2023 and its Director from October 2022.取締役名称ポジション在職期間報酬所有権Joakim GranemoCEO & Director3.6yrsデータなしデータなしUlrica KarlssonCFO & Directorno dataSEK 945.00kデータなしHelene OlssonDirector of Cybergene ABno dataSEK 605.00kデータなしMikael KubistaDirector2.3yrsSEK 25.00kデータなしMikael HavsjoDirector15.2yrsSEK 50.00kデータなしArtur AiraChairman8.3yrsSEK 100.00kデータなしTobias SchönDirector3.3yrsSEK 50.00k6.85% € 132.9kNeven ZoricDirector6.3yrsSEK 50.00kデータなしClaes GustafssonDirector of Techtum Lab ABno dataSEK 976.00kデータなしもっと見る5.0yrs平均在職期間56yo平均年齢経験豊富なボード: 4MBの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 09:24終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Level Bio AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.
お知らせ • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 20No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 02Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO).Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT.
お知らせ • Feb 12Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million.Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026. The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.
Reported Earnings • Apr 26First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023).
お知らせ • Mar 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024
お知らせ • Mar 20AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024.
Reported Earnings • Feb 25Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022)Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022).
お知らせ • Jan 24AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024
Reported Earnings • Oct 29Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr6.54m (up 19% from 3Q 2022). Net loss: kr2.30m (loss widened 93% from 3Q 2022).
お知らせ • Sep 27AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023
Reported Earnings • Aug 28Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022).
お知らせ • Jul 26AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023
お知らせ • May 31AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023.
Reported Earnings • Apr 20First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022).
Buying Opportunity • Apr 03Now 34% undervalued after recent price dropOver the last 90 days, the stock is down 31%. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.
Buying Opportunity • Mar 07Now 37% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Feb 24Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021)Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021).
お知らせ • Jan 18AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021).
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021)First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 22First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates.
Reported Earnings • Nov 01Third quarter 2021 earnings releasedThe company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020).
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue.